Medicare Enrolled
Dr. Pierre Minerva, M.D.
Rheumatology · Bryn Mawr, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Minerva from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Minerva?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Minerva
Dr. Pierre Minerva is a rheumatology specialist in Bryn Mawr, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Minerva performed 27,576 Medicare services across 1,055 unique beneficiaries.
Between the years covered by Open Payments, Dr. Minerva received a total of $13,697 from 61 pharmaceutical and/or device companies across 666 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Minerva is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 28% volume in PA
$13,697 industry payments
Medicare Practice Summary
Medicare Utilization ↗27,576
Medicare services
Top 28% in PA for rheumatology
1,055
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,379 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 8,460 | $18 | $40 |
| Romosozumab injection (Evenity) for osteoporosis | 8,400 | $8 | $20 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
8,260 | $26 | $115 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
771 | $96 | $218 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
345 | $6 | $113 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
294 | $12 | $50 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
275 | $111 | $322 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
230 | $1 | $11 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
117 | $24 | $72 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
113 | $62 | $171 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
64 | $50 | $170 |
| Injection, methylprednisolone acetate, 40 mg | 58 | $6 | $20 |
| New patient office visit, complex (60-74 min) | 39 | $173 | $308 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
39 | $5 | $15 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
38 | $135 | $278 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $67 | $139 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
16 | $44 | $107 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
14 | $32 | $40 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
12 | $76 | $110 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
12 | $138 | $250 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
31.2% high complexity
65.5% medium
3.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,697
Total received (2018-2024)
Avg $1,957/year across 7 years
Top 23% in PA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
61
Companies
666
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,659 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$37 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,354
2023
$2,176
2022
$2,069
2021
$1,470
2020
$1,292
2019
$1,979
2018
$2,355
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$362
AstraZeneca Pharmaceuticals LP
$311
Alexion Pharmaceuticals, Inc.
$216
Amgen Inc.
$208
Fresenius Kabi USA, LLC
$164
UCB, Inc.
$144
Genentech USA, Inc.
$111
Novartis Pharmaceuticals Corporation
$110
ANI Pharmaceuticals, Inc.
$108
Lilly USA, LLC
$96
Janssen Biotech, Inc.
$85
PFIZER INC.
$76
Sandoz Inc.
$58
GENZYME CORPORATION
$49
Boehringer Ingelheim Pharmaceuticals, Inc.
$48
Actelion Pharmaceuticals US, Inc.
$34
Organon Llc
$34
Radius Health, Inc.
$26
Aurinia Pharma U.S., Inc.
$22
Kyowa Kirin, Inc.
$20
SCILEX PHARMACEUTICALS INC.
$20
Mallinckrodt Hospital Products Inc.
$18
Fidia Pharma USA Inc.
$18
Alvogen Inc
$17
Top 3 companies account for 37.8% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$1,904
ABBVIE INC.
$1,046
AstraZeneca Pharmaceuticals LP
$964
Genentech USA, Inc.
$824
UCB, Inc.
$807
Novartis Pharmaceuticals Corporation
$719
Janssen Biotech, Inc.
$705
PFIZER INC.
$634
Alexion Pharmaceuticals, Inc.
$442
Boehringer Ingelheim Pharmaceuticals, Inc.
$389
Radius Health, Inc.
$364
Lilly USA, LLC
$326
E.R. Squibb & Sons, L.L.C.
$314
ANI Pharmaceuticals, Inc.
$236
AbbVie Inc.
$216
AbbVie, Inc.
$214
Mallinckrodt Hospital Products Inc.
$213
GENZYME CORPORATION
$212
GlaxoSmithKline, LLC.
$194
Fresenius Kabi USA, LLC
$189
Flexion Therapeutics, Inc.
$161
Amarin Pharma Inc.
$126
Insmed, Inc.
$125
Novo Nordisk Inc
$125
Janssen Scientific Affairs, LLC
$125
Actelion Pharmaceuticals US, Inc.
$123
Paratek Pharmaceuticals, Inc.
$123
Aurinia Pharma U.S., Inc.
$121
Otsuka America Pharmaceutical, Inc.
$120
Bioventus LLC
$104
Sandoz Inc.
$101
Celgene Corporation
$100
Horizon Therapeutics plc
$97
Mallinckrodt Enterprises LLC
$91
SANOFI-AVENTIS U.S. LLC
$90
Merck Sharp & Dohme Corporation
$89
Exeltis, USA Inc.
$81
Sobi, Inc
$79
Cumberland Pharmaceuticals, Inc.
$71
Antares Pharma, Inc.
$64
DePuy Synthes Sales Inc.
$64
Hikma Pharmaceuticals USA
$63
IBSA Pharma Inc.
$56
Mallinckrodt LLC
$51
SOBI, INC
$38
Kiniksa Pharmaceuticals, Ltd.
$36
Organon Llc
$34
Organon LLC
$34
Fidia Pharma USA Inc.
$34
Ultragenyx Pharmaceutical Inc.
$33
Ironwood Pharmaceuticals, Inc
$30
MEDEXUS PHARMA, INC.
$29
Takeda Pharmaceuticals U.S.A., Inc.
$29
Ferring Pharmaceuticals Inc.
$25
Kyowa Kirin, Inc.
$20
SCILEX PHARMACEUTICALS INC.
$20
Alvogen Inc
$17
MEDAC PHARMA, INC.
$15
Celltrion USA Inc.
$14
West-Ward Pharmaceuticals
$14
Mission Pharmacal Company
$12
Top 3 companies account for 28.6% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Aimovig · Aquoral · Arcalyst · Arikayce · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · Cryvista · DUZALLO · Durolane · EUFLEXXA · EVENITY · Enbrel · FARXIGA · FASENRA · FORTEO · HADLIMA · HUMIRA · HYMOVIS · HYRIMOZ · Humira · IDACIO · ILARIS · INFLECTRA · JARDIANCE · JYNARQUE · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUMIZYME · LUPKYNIS · LYRICA · Licart · MONOVISC · Mitigare · NUCALA · NUZYRA · OFEV · OPSUMIT · ORENCIA · ORTHOVISC · Otezla · Otrexup · PURIFIED CORTROPHIN GEL · Prolia · REDITREX · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · SPEVIGO · STELARA · STRENSIQ · SYNVISC-ONE · Strensiq · TAGRISSO · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Tirosint · Tyenne · Tymlos · UBRELVY · UPTRAVI · Uloric · Vascepa · Wegovy · XELJANZ · YUFLYMA · ZTLido · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Rheumatologists within 10 mi
178
Per 100K population
30.9
County median income
$88,576
Nearest hospital
BRYN MAWR HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Minerva is a mixed practice specialist, with above-average Medicare volume (top 28% in PA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Minerva experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Minerva performed 8,460 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Minerva receive payments from pharmaceutical companies?
Yes. Dr. Minerva received a total of $13,697 from 61 companies across 666 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Minerva's costs compare to other rheumatologists in Bryn Mawr?
Dr. Minerva's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Minerva) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Bryn Mawr
Browse rheumatologists in Bryn Mawr ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in PA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in PA
Which PA rheumatologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology